In Silico Analyses on the Comparative Potential of Therapeutic Human Monoclonal Antibodies Against Newly Emerged SARS-CoV-2 Variants Bearing Mutant Spike Protein

Since the start of the pandemic, SARS-CoV-2 has already infected more than 250 million people globally, with more than five million fatal cases and huge socio-economic losses. In addition to corticosteroids, and antiviral drugs like remdesivir, various immunotherapies including monoclonal antibodies...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Nabarun Chandra, Chakraborty, Pritha, Bayry, Jagadeesh, Mukherjee, Suprabhat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784557/
https://www.ncbi.nlm.nih.gov/pubmed/35082779
http://dx.doi.org/10.3389/fimmu.2021.782506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784557/
https://www.ncbi.nlm.nih.gov/pubmed/35082779
http://dx.doi.org/10.3389/fimmu.2021.782506

Ejemplares similares